Guidelines (ESC & NICE) for the pharmacological management of angina pectoris – What’s new?
Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.
Related articles
09/04/2017 - ESC Congress 2017 – Highlights Day 1 - Prof Juan Carlos Kaski, St George's, University of London, UK
01/02/2017 - Recurrent or persistent angina after coronary artery revascularisation and stent implantation - Prof Juan Carlos Kaski, St George's, University of London, UK
10/03/2016 - Female-specific risk variables for CVD risk prediction - Prof Angela Maas, University Medical Center, The Netherlands
09/05/2016 - ESC Congress 2016 HIGHLIGHTS - Prof Juan Carlos Kaski, St George's, University of London, UK
08/08/2016 - High blood pressure: Guidelines for treatment & high pressure goals - Prof Bryan Williams, University College London, UK
07/25/2016 - Refractory Angina Pectoris: how important an issue? - Prof Juan Carlos Kaski, St George's, University of London, UK
06/27/2016 - Ranolazine for management of microvascular angina - Prof Juan Carlos Kaski, St George's, University of London, UK
12/14/2015 - MV angina treatment: improving vascular function, preventing coronary artery spasm - Professor Juan Carlos Kaski, Director of the Cardiovascular and Cell Sciences Research Institute at St George’s University of London, UK
12/03/2015 - Healing broken hearts: Takotsubo prognosis ‘quite good’ - Professor Juan Carlos Kaski, Director of the Cardiovascular and Cell Sciences Research Institute at St George’s University of London, UK
11/10/2015 - Inter-atrial block- The Bayes Syndrome: clinical implications - Prof Juan Carlos Kaski, UK, and Dr Dr Antonio Bayes de Luna, Spain
Leave a Reply
You must be logged in to post a comment.